Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

ELTX

Live52w high -33.4%

Core line items from ELTX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Elicio Therapeutics, Inc.·Source: SEC EDGAR companyfacts

Metric	Annual 2022 2022-12-31	Annual 2021 2021-12-31	Annual 2020 2020-12-31
Revenue	$2.30M	$27.51M	$193.00K
Operating Income	$-23.73M	$-39.31M	$-55.27M
Net Income	$-28.21M	$-54.57M	$-80.11M
EPS (Diluted)	$-89.27	$-1.93	$-5.43
Total Assets	$22.66M	$96.51M	$47.35M
Total Liabilities	$13.75M	$15.01M	$137.80M
Cash & Equivalents	$6.16M	$88.76M	$34.61M
Free Cash Flow OCF − CapEx	$-22.83M	$-53.02M	$-22.93M
Shares Outstanding	320.28K	29.96M	15.32M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from ELTX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -33.4%

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: Elicio Therapeutics, Inc.·Source: SEC EDGAR companyfacts

Metric	Annual 2022 2022-12-31	Annual 2021 2021-12-31	Annual 2020 2020-12-31
Revenue	$2.30M	$27.51M	$193.00K
Operating Income	$-23.73M	$-39.31M	$-55.27M
Net Income	$-28.21M	$-54.57M	$-80.11M
EPS (Diluted)	$-89.27	$-1.93	$-5.43
Total Assets	$22.66M	$96.51M	$47.35M
Total Liabilities	$13.75M	$15.01M	$137.80M
Cash & Equivalents	$6.16M	$88.76M	$34.61M
Free Cash Flow OCF − CapEx	$-22.83M	$-53.02M	$-22.93M
Shares Outstanding	320.28K	29.96M	15.32M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.